Why Organizations Choose ATEK Over Eupry
Eupry emerged from an unlikely origin story: a 2012 collaboration between UNICEF and the Technical University of Denmark aimed at solving temperature compliance for medicine storage in developing countries. Formally incorporated in 2014 in Copenhagen, the company grew into a cloud-native pharmaceutical monitoring platform at the doorstep of Denmark’s pharma corridor — Novo Nordisk, Lundbeck, and AstraZeneca are all within reach. With approximately $26.9M in venture funding and a patented calibration technology, Eupry represents the modern European approach to pharma environmental monitoring. For North American organizations evaluating Eupry, the central question is whether a Copenhagen-headquartered startup with strong European pharma credentials can deliver the local support, regulatory expertise, and operational continuity that facilities in Eastern and Central time zones require.
Understanding Eupry
Eupry ApS was founded in 2014 by a team of DTU graduates who recognized that temperature compliance in regulated industries was unnecessarily manual and fragmented. The company’s roots in a UNICEF project gave it an early orientation toward solving real-world compliance problems, and the Copenhagen location placed it within Denmark’s dense pharmaceutical ecosystem. Novo Nordisk audited Eupry’s platform and awarded a “High” compliance rating in June 2023 — a meaningful validation from one of the world’s largest pharmaceutical companies.
The company has grown to approximately 80 employees serving over 500 customers across 6,000+ locations in 50 countries. In December 2024, Eupry secured a EUR 23M Series A round, signaling investor confidence but also confirming the company remains in a growth-dependent phase. Products span WiFi and NB-IoT wireless data loggers (DW1ST, DW2ST series), the cloud monitoring platform hosted on AWS, and the EasyMap validation software for temperature mapping exercises.
Eupry’s recognized strengths include:
- Cloud-Native Platform Built for Pharma — Unlike legacy monitoring vendors who retrofitted existing systems, Eupry was designed from inception as a cloud-first GxP platform with automatic updates, validated software architecture, and ISO 27001-certified data security running on AWS infrastructure
- Patented ALIIO Calibration Technology — The 2023-patented ALIIO system allows on-the-wall sensor tip replacement rather than shipping entire data loggers for calibration, with ISO 17025-accredited tips arriving by mail and clicking onto existing loggers in seconds — Novozymes reported calibrating 40 loggers in under an hour using this approach
- Danish Pharma Ecosystem Credibility — Headquartered minutes from Novo Nordisk’s global headquarters, Eupry has earned direct validation from major European pharmaceutical companies and built deep expertise in EU GMP Annex 11, GDP compliance, and European regulatory frameworks
Common Challenges with Eupry
Organizations evaluating or currently using Eupry frequently encounter these considerations:
- Copenhagen business hours for North American facilities: Eupry’s core support team operates from Central European Time. When a monitoring system flags a temperature excursion at 2 AM Eastern, the Copenhagen team is six hours ahead — and may not have overnight escalation coverage staffed by specialists who understand your specific sensor deployment and facility layout
- FDA 21 CFR Part 11 as an add-on module: Unlike platforms where Part 11 compliance is built into the core architecture, Eupry delivers FDA 21 CFR Part 11 compliance through a separate module that must be added to the service plan. Organizations must explicitly request and enable this module, raising questions about whether the base platform captures the full audit trail and electronic signature functionality before the module is activated
- Startup financial risk in a regulated environment: With approximately 80 employees and $26.9M in venture funding, Eupry’s long-term stability depends on continued growth, future funding rounds, or potential acquisition. For pharmaceutical facilities that validate monitoring systems with multi-year qualification lifecycles, the business continuity risk of a venture-backed startup merits consideration during vendor evaluation
- European-first calibration and hardware logistics: Eupry’s ISO 17025-accredited calibration services and hardware operations are based in Denmark. While the ALIIO sensor-tip system reduces calibration frequency, initial deployments, hardware replacements, and any non-standard service requests involve transatlantic logistics with associated shipping times and customs considerations
- No French-language support for Canadian facilities: Eupry does not offer bilingual English/French support. For Quebec-based pharmaceutical facilities where French documentation and regulatory communication are operational requirements, this creates a compliance communication gap that internal resources must fill
How ATEK Addresses These Needs
24/7 Support Without the Atlantic Crossing: For organizations considering Eupry’s Copenhagen-based support model, ATEK’s Montreal-based monitoring specialists eliminate the overnight coverage gap entirely. When Eupry’s CET business hours end and your North American facility is still running a second or third shift, ATEK’s team is available with a guaranteed 5-minute live response. The support team handles pharmaceutical environmental monitoring exclusively — not general SaaS queries — and provides native bilingual service for facilities across Canada, including Quebec operations where French-language support is a regulatory expectation.
A2LA-Accredited Calibration Without Transatlantic Logistics: Eupry’s ALIIO calibration technology is genuinely innovative for reducing on-site calibration time, but the ISO 17025-accredited sensor tips still ship from Denmark. ATEK’s in-house A2LA-accredited calibration lab in Canada processes calibrations domestically — no customs declarations, no transatlantic shipping windows, no import duty paperwork. For organizations running calibration cycles across dozens or hundreds of monitoring points, domestic turnaround measured in days rather than weeks keeps compliance schedules tight.
Native FDA 21 CFR Part 11 Compliance — No Module Required: Where Eupry requires organizations to add a separate compliance module to their service plan for Part 11 functionality, ATEK’s platform includes FDA 21 CFR Part 11 compliance natively — electronic signatures, complete audit trails, and ALCOA+ data integrity principles are built into the core architecture. Every monitoring interaction generates compliant records from day one, without additional configuration, module activation, or tier-dependent feature gating.
Transparent Pricing Without Module Stacking: Eupry’s subscription model offers financial predictability at the base level, but compliance modules, mapping tools, and enterprise features add layers of cost. ATEK bundles hardware, cloud platform, calibration, full GxP compliance, validation documentation, training, and 24/7 support into a single per-monitoring-point rate. One invoice, complete regulatory compliance included, no module upgrades required.
Side-by-Side Comparison
| Factor | Eupry | ATEK | Advantage |
|---|---|---|---|
| Cloud-native architecture | Born cloud-native (2014) | Cloud-native | Comparable |
| Patented calibration technology | ALIIO sensor-tip swap | Traditional A2LA-accredited | Eupry |
| European pharma ecosystem | Copenhagen HQ, Novo Nordisk audited | North American focus | Eupry |
| Temperature mapping capability | EasyMap validation software | Limited | Eupry |
| FDA 21 CFR Part 11 | Add-on module | Native, included | ATEK |
| Support response time | CET business hours | 5-minute guarantee, 24/7/365 | ATEK |
| Bilingual support (EN/FR) | Not available | Montreal-based, native French | ATEK |
| North American calibration | Ships from Denmark | A2LA-accredited lab in Canada | ATEK |
| Canadian data hosting | AWS (EU/global regions) | Canadian-hosted, PIPEDA-compliant | ATEK |
| Pricing transparency | Subscription + module add-ons | All-inclusive per point | ATEK |
Who Benefits Most from Switching
- North American pharmaceutical facilities currently using Eupry who find that CET business hours support and transatlantic hardware logistics create operational friction for facilities running 24/7 in Eastern or Central time zones
- Organizations approaching Eupry subscription renewal who want to evaluate whether a platform with native FDA 21 CFR Part 11 compliance — without add-on module requirements — better fits their regulatory posture and total cost of ownership
- Canadian facilities needing bilingual support and data residency where French-language documentation, PIPEDA-compliant Canadian data hosting, and local A2LA-accredited calibration are operational requirements rather than nice-to-haves
- Risk-conscious procurement teams evaluating vendor stability who prefer an established monitoring partner over a venture-backed startup still in its growth-funding phase
Making the Transition
Switching from Eupry to ATEK follows a structured approach designed around Eupry’s cloud-based ecosystem:
- Deployment mapping — We document your current Eupry configuration: data logger placement across monitoring zones, ALIIO sensor-tip calibration schedules, alarm rules and notification workflows, EasyMap validation records, and any integration points with quality management or building management systems
- Parallel monitoring — ATEK wireless sensors install alongside existing Eupry data loggers. Both systems capture data simultaneously during the qualification period, establishing reading correlation and ensuring continuous compliance coverage without monitoring gaps between platforms
- Compliance validation — Complete IQ/OQ/PQ documentation is included. Our team addresses the specific transition from Eupry’s compliance framework — including mapping any Part 11 module configurations — to ATEK’s cloud-native GxP platform, ensuring audit trail continuity and regulatory documentation meets your QA team’s requirements
- Phased cutover — Monitoring transitions zone by zone, allowing operations to validate each area before decommissioning Eupry loggers. Eupry subscription cancellation timing is coordinated to avoid overlap charges while maintaining continuous compliance
When Eupry May Be the Right Fit
Eupry is a strong choice for organizations headquartered in Europe whose primary regulatory framework is EU GMP Annex 11 and GDP. The Copenhagen location provides natural proximity to the Danish and Scandinavian pharmaceutical ecosystem, and the patented ALIIO calibration technology offers genuine operational advantages for large-scale European deployments where on-the-wall sensor-tip replacement eliminates traditional calibration logistics. Organizations that need integrated temperature mapping alongside continuous monitoring may also value Eupry’s EasyMap validation software. For European-first operations with dedicated internal teams able to manage the FDA compliance module configuration, Eupry’s modern cloud-native platform is a legitimate alternative to legacy incumbents.
When ATEK Is the Better Choice
Choose ATEK when you need:
- 24/7 live monitoring support from North America — not Copenhagen business hours with a six-hour time zone gap to Eastern
- Native FDA 21 CFR Part 11 compliance built into the core platform, not a separate module added to your subscription tier
- A2LA-accredited calibration in Canada without shipping sensor tips or hardware across the Atlantic and through customs
- Bilingual English/French support for Quebec pharmaceutical facilities from a Montreal-based team that understands Health Canada and provincial regulatory requirements
- Canadian data hosting with PIPEDA, FIPPA, and provincial privacy compliance — not AWS regions determined by a European vendor’s infrastructure decisions
Start with a free assessment to see how ATEK compares against your current Eupry deployment.
Frequently Asked Questions
Is ATEK FDA 21 CFR Part 11 compliant like Eupry?
Yes. Both ATEK and Eupry address FDA 21 CFR Part 11 requirements, but the implementation differs. ATEK’s platform includes Part 11 compliance natively — electronic signatures, complete audit trails, and ALCOA+ data integrity are built into the core architecture. Eupry delivers Part 11 compliance through a separate module that must be added to the base service plan. For organizations where Part 11 compliance is non-negotiable from day one, ATEK’s approach eliminates the module activation step.
How does Eupry’s ALIIO calibration compare to ATEK’s calibration approach?
Eupry’s patented ALIIO technology is genuinely innovative — swapping sensor tips on the wall rather than removing entire loggers reduces on-site calibration time significantly. However, the ISO 17025-accredited sensor tips ship from Denmark. ATEK’s A2LA-accredited calibration lab in Canada handles full sensor calibration domestically with turnaround measured in days rather than transatlantic shipping windows. The trade-off is on-site convenience (Eupry) versus domestic logistics and accredited lab proximity (ATEK).
How long does it take to migrate from Eupry to ATEK?
Typical migration timelines range from 2-6 weeks depending on the number of monitoring points and facility complexity. Because both Eupry and ATEK are cloud-based platforms, the parallel monitoring phase — where ATEK sensors run alongside existing Eupry data loggers — is straightforward to manage. Organizations with multiple facilities usually transition zone by zone rather than executing a full-site cutover.
Is Eupry too small or risky as a monitoring vendor?
Eupry has grown to approximately 80 employees serving 500+ customers across 50 countries, with $26.9M in venture funding. That is meaningful traction. The consideration is not whether Eupry is viable today, but whether a venture-backed company in its growth phase provides the long-term stability that pharmaceutical monitoring system qualification cycles demand. ATEK offers the assurance of an established monitoring partner focused exclusively on the North American regulated market.
Does ATEK offer temperature mapping like Eupry’s EasyMap?
ATEK’s primary focus is continuous environmental monitoring with GxP compliance for pharmaceutical facilities, not standalone temperature mapping exercises. Eupry’s EasyMap validation software addresses mapping as a distinct capability. Organizations that require both mapping and monitoring may use ATEK for continuous compliance monitoring alongside dedicated mapping tools or services during qualification projects.
Can ATEK support facilities that also have European operations using Eupry?
Yes. ATEK focuses on North American facility monitoring, and many organizations run different monitoring vendors across regions based on local support requirements. Using ATEK for Canadian and US facilities while maintaining Eupry for European operations is a practical approach that ensures each region receives locally supported, time zone-appropriate monitoring coverage.